When looking back over the last few years, the highly visible and popular bio-services sector has virtually lived up to its initial potential. The bio-service income and volume data includes contract manufacturing, contract research, and clinical research. Many industry analysts and leaders are optimistic about the bioservices sector's potential and prospects. For instance, around 120 clinical studies were subcontracted to India a few years ago, and only about 11 were properly registered with the Clinical Trial Registry of India (CTRI). 600 innovative medication, medical device, therapy, and surgical procedure trials are now underway in India. With the inherent cost benefits and significant investments and consolidation, new set-ups and subsidiaries of bio-pharma manufacturers and research labs, in new locations and clinical data management, are projected to auger well for the global growth of this sector.
